Ucb S.A. (OP:UCBJF)
Price and Volume
Detailed Quote| Volume | 265 |
| Open | 321.05 |
| Bid (Size) | N/A (0) |
| Ask (Size) | N/A (0) |
| Prev. Close | 305.84 |
| Today's Range | 306.00 - 321.05 |
| 52wk Range | 219.60 - 345.39 |
| Shares Outstanding | N/A |
| Dividend Yield | N/A |
Top News
More News
Performance
52-Week Range
8.4% below 52-week high
316.41
219.6052W Low
345.3952W High
1 Week
1.4% below 1-week high
289.011W Low
321.051W High
Ucb S.A. (UCBJF) traded between $219.60 and $345.39 over the past 52 weeks and last traded at $316.41, 8.4% below its 52-week high. Over the past week it ranged between $289.01 and $321.05.
Past 12 Months
1W
+$23.02
1M
+$69.77
3M
+$56.82
6M
+$42.16
YTD
+$33.53
1Y
+$51.25
UCBJF was +19.3% over the past year, +15.4% over six months, +11.9% year to date, +7.8% in the last week.
12 Months vs Market
UCBJF
+19.3%
DIA
+9.7%
SPY
+11.9%
QQQ
+12.5%
IWM
+15.1%
Over the past 12 months UCBJF returned +19.3% versus DIA (Dow) +9.7%, SPY (S&P 500) +11.9%, QQQ (Nasdaq 100) +12.5% and IWM (Russell 2000) +15.1%.
Volume & Liquidity
0.35× 3-mo avg
Today 265
3-mo avg 768.0
1W
158.0
1M
466.0
3M
768.0
6M
761.0
YTD
799.0
1Y
755.0
UCBJF most recently traded 265 shares against a 3-month average daily volume of 768.0.
More News
Read More
UCB's Rare Childhood Epilepsy Drug Scores FDA Approval ↗
March 28, 2022
UCB Gets EU Approval For Bimekizumab In Psoriasis ↗
August 25, 2021
Frequently Asked Questions
Is Ucb S.A. publicly traded?
Yes, Ucb S.A. is publicly traded.
What exchange does Ucb S.A. trade on?
Ucb S.A. trades on the OTC Traded
What is the ticker symbol for Ucb S.A.?
The ticker symbol for Ucb S.A. is UCBJF on the OTC Traded
What is the current price of Ucb S.A.?
The current price of Ucb S.A. is 316.41
When was Ucb S.A. last traded?
The last trade of Ucb S.A. was at 10/29/26 03:30 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.